Related Experiment Video
Updated: Nov 2, 2025
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm
Petros Giannikopoulos1, David M Parham2
1Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
Abstract:
For the past 40 years, progress in rhabdomyosarcoma (RMS) has been focused on understanding its molecular basis and characterizing the mutations that drive its tumorigenesis and progression. Genetic predisposition to RMS has allowed discovery of key genetic pathways and driver mutations. Subclassification of RMS into embryonal (ERMS) and alveolar (ARMS) subtypes has shifted from histology to PAX-FOXO1 fusion status, and new driver mutations have been found in spindle cell RMS. Comprehensive molecular profiling leveraging genome-scale next-generation sequencing (NGS) indicates that the RAS/RAF/PI3K axis is mutated in the majority of ERMS and modulated by downstream effects of PAX-FOXO1 fusions in ARMS. Because of the continued poor outcome of high-risk RMS, a variety of molecular targets have been or are now being tested in current or recent therapy trials. New techniques such as single cell sequencing, spatial multi-omics, and CRISPR/Cas9 genome editing offer potential for further discovery, but a need for clinically annotated specimens persists.
Insights
Rhabdomyosarcoma research advances understanding of its molecular drivers, including genetic predispositions and key mutations. New therapies target identified molecular pathways, aiming to improve outcomes for high-risk patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Rhabdomyosarcoma (RMS) research has focused on its molecular basis and mutations for 40 years.
- Genetic predisposition studies have revealed key pathways and driver mutations in RMS.
- Subclassification evolved from histology to PAX-FOXO1 fusion status, identifying new mutations in spindle cell RMS.
Purpose of the Study:
- To review the molecular basis of rhabdomyosarcoma (RMS).
- To highlight advancements in understanding RMS tumorigenesis and progression.
- To discuss current and future therapeutic strategies targeting molecular alterations.
Main Methods:
- Comprehensive molecular profiling using genome-scale next-generation sequencing (NGS).
- Analysis of genetic predispositions and driver mutations.
- Review of current and recent therapy trials incorporating molecular targets.
Main Results:
- The RAS/RAF/PI3K axis is frequently mutated in embryonal RMS (ERMS).
- PAX-FOXO1 fusions modulate downstream effects in alveolar RMS (ARMS).
- High-risk RMS continues to have poor outcomes, necessitating novel therapeutic approaches.
Conclusions:
- Molecular profiling has elucidated key pathways in RMS subtypes.
- Targeting identified molecular alterations is crucial for improving RMS treatment outcomes.
- Advanced techniques like single-cell sequencing and CRISPR/Cas9 hold promise for future discoveries, pending availability of annotated specimens.
More Related Videos
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
